Cantor


Cantor Reduces Ligand Pharmaceuticals Price Target Following 3Q14 Results

In a research report sent to investors today, Cantor analyst Irina Rivkind reiterated a Hold rating on Ligand Pharmaceuticals (NASDAQ:LGND) and reduced her share price target to $43 …

UPDATE: Cantor Remain Buyers Of Twitter Following Earnings

In a research report released Tuesday, Cantor analyst Youssef Squali assigned a Buy rating on Twitter Inc (NYSE:TWTR) with a $58 price target, as the …

Cantor Maintains Buy On Facebook Ahead Of 3Q Results

In a research report released Monday, Cantor analyst Youssef Squali assigned a Buy rating on Facebook (NASDAQ:FB) with an $82 price target. The report …

Cantor Sets Expectations On LinkedIn Ahead Of 3Q14 Earnings

In a research report issued today, Cantor analyst Youssef Squali maintained a Buy rating on LinkedIn Corp (NYSE:LNKD) with a $250 price target, ahead …

Cantor Reiterates Hold On Shares Of VistaPrint NV, $52 PT

In a research report issued this morning, Cantor analyst Youssef Squali reiterated a Hold rating on VistaPrint NV (NASDAQ:VPRT) with a price target …

Shutterfly: In-Line Quarter Likely Ahead Of The Seasonally Strong 4Q

In a research report published this morning, Cantor analyst Youssef Squali assigned a Buy rating on Shutterfly (NASDAQ:SFLY) with a $60 price target, …

Twitter: Solid 3Q:14 Results Are Expected, Says Cantor

In a research report issued this morning, Cantor analyst Youssef Squali maintained a Buy rating on Twitter Inc (NYSE:TWTR) with a $58 price target, …

Cantor Maintains Buy On comScore Shares, $42 PT

In a research note released this morning, Cantor analyst Youssef Squali maintained a Buy rating on comScore Inc (NASDAQ:SCOR) with a price target …

Cantor Sets Expectations On Expedia Into 3Q14 Earnings

In a research report issued this morning, Cantor analyst Naved Khan reiterated a Buy rating on Expedia (NASDAQ:EXPE) with a $92 price target, ahead …

Cantor Raises Sucampo Price Target To $14, As Takeda Continues To Invest in Amitiza

In a research note issued to investors today, Cantor analyst Irina Rivkind assigned a Buy rating on Sucampo (NASDAQ:SCMP) and raised her price target to $14 …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts